StartseiteMCPWorkbenchSkills
StartseiteWorkbenchBenachrichtigungenMein Bereich
llms.txt · MCP-AnleitungDatenschutz · Nutzungsbedingungen · Supportv1.8.3
  1. Startseite
  2. /Verbindung

Gefitinib

HCID 123631
Neue Reaktion
Drucken

Daten werden ergänzt – lade die Seite später neu, um den aktuellen Stand zu sehen

GrundinformationenÜberblickNamen und BezeichnerEigenschaftenSicherheit und RegulatorischesChemie und IndustrieZugehörige ReaktionenNotizen zur Verbindung
TeilstruktursucheÄhnliche Strukturen suchen

Grundinformationen

CAS
184475-35-2
Standard-SMILES
COc1cc2ncnc(Nc3ccc(F)c(Cl)c3)c2cc1OCCCN1CCOCC1
InChIKey
XGALLCVXEZPNRQ-UHFFFAOYSA-N
Summenformel
C22H24ClFN4O3
Durchschnittliche Molmasse
446,9 g/mol
Monoisotopische Masse
446,1520965

Überblick

Gefitinib is a member of the class of quinazolines that is quinazoline which is substituted by a (3-chloro-4-fluorophenyl)nitrilo group, 3-(morpholin-4-yl)propoxy group and a methoxy group at positions 4,6 and 7, respectively. An EGFR kinase inhibitor used for the treatment of non-small cell lung cancer. It has a role as an antineoplastic agent and an epidermal growth factor receptor antagonist. It is an aromatic ether, a member of quinazolines, a member of morpholines, a secondary amino compound, a tertiary amino compound, a member of monochlorobenzenes and a member of monofluorobenzenes.

Namen und Bezeichner

Bevorzugter Name
Gefitinib
IUPAC
N-(3-chloro-4-fluorophenyl)-7-methoxy-6-(3-morpholin-4-ylpropoxy)quinazolin-4-amine
Englischer Name
Gefitinib
Summenformel
C22H24ClFN4O3
Molmasse
446.9

Namen und Synonyme

Gefitinib184475-35-2IressaZD1839IrressatZD 1839ZD-1839gefitinibumN-(3-chloro-4-fluorophenyl)-7-methoxy-6-[3-(morpholin-4-yl)propoxy]quinazolin-4-amineN-(3-chloro-4-fluorophenyl)-7-methoxy-6-[3-(4-morpholinyl)propoxy]-4-quinazolinamine4-(3'-Chloro-4'-fluoroanilino)-7-methoxy-6-(3-morpholinopropoxy)quinazolineN-(3-chloro-4-fluorophenyl)-7-methoxy-6-(3-morpholin-4-ylpropoxy)quinazolin-4-amine
Weitere Namen anzeigen
GefinitibGifitinibGefltinibGefitinib TabletsN-(3-Chlor-4-fluorophenyl)-7-[methoxy-6-[(3-morpholin-4-yl)propoxyl]-quinazolin-4-yl]amineressaCS-524efitinib
DTXSID8041034NSC-759856S65743JHBSCHEBI:49668DTXCID6021034NSC7150554-Quinazolinamine, N-(3-chloro-4-fluorophenyl)-7-methoxy-6-(3-(4-morpholinyl)propoxy)-N-(3-chloro-4-fluorophenyl)-7-methoxy-6-(3-(4-morpholinyl)propoxy)-4-quinazolinamine

Eigenschaften

Berechnete StruktureigenschaftenWird ergänzt

XLogP
4,1
Polarare Oberfläche (TPSA)
68,7 Ų
H-Brücken-Donoren
1
H-Brücken-Akzeptoren
8
Frei drehbare Bindungen
8
Schwere Atome
31
Formalladung
0
Komplexität
545

Experimentelle und physikochemische Eigenschaften

Drugs · 2 Einträge

Pharmaceuticals -> Antineoplastic and immunomodulating agents -> Antineoplastic agents

Pharmaceuticals -> Listed in ZINC15

LogP3.2
Solubility · 2 Einträge

Sparingly soluble (<pH4)

2.70e-02 g/L

Human Drugs · 5 Einträge

Breast Feeding; Lactation; Antineoplastic Agents; Enzyme Inhibitors; Protein Kinase Inhibitors; Signal Transduction Inhibitors; Tyrosine Kinase Inhibitors;

FDA approved drugs -> Active ingredient

EMA approved medicines: Human medicine

FDA approved drugs -> Active ingredient

Targeted therapies

Physical DescriptionSolid
Dissociation Constants5.4 and 7.2

Physikochemische Eigenschaften

Schmelzpunkt
119 · 119-1200C

Sicherheit und Regulatorisches

Sicherheitsangaben dienen nur zur Orientierung und ersetzen weder das Sicherheitsdatenblatt (SDB) des Lieferanten noch geltende Vorschriften oder eine fachliche Bewertung.

GHS-Klassifizierung

GHS Classification · 4 Einträge

Danger

H302 (100%): Harmful if swallowed [Warning Acute toxicity, oral]

P203, P260, P264, P264+P265, P270, P273, P280, P301+P317, P302+P352, P305+P354+P338, P317, P318, P319, P321, P330, P332+P317, P362+P364, P391, P405, and P501 (click each P-code to see the statement)

Aggregated GHS information provided per 80 reports by companies from 15 notifications to the ECHA C&L Inventory. Each notification may be associated with multiple companies.

Gefahrenhinweise

Hazard Classes and CategoriesAcute Tox. 4 (100%)

Toxikologische Informationen

Hepatotoxicity · 1 Eintrag

In large early clinical trials, elevations in serum aminotransferase levels occurred in 9% to 13% of patients treated with standard doses of gefitinib, and 2% to 4% of patients had to stop therapy because of elevations above 5 times the upper limit of normal. Serum enzyme elevations typically arise after 4 to 12 weeks of treatment with a hepatocellular pattern. Immunoallergic and autoimmune features have not been described, but rash is common in patients receiving gefitinib. Most cases of liver injury due to gefitinib in the literature have been minimally or not symptomatic, and the injury resolved within 1 to 2 months of stopping the drug. Restarting therapy was usually but not always followed by rapid recurrence of serum enzyme elevations, and corticosteroid therapy did not appear to prevent this recurrence. In some instances, lower doses were tolerated with minimal or no ALT elevations. Periodic monitoring of liver tests during therapy is recommended. Despite the frequency of serum aminotransferase elevations during gefitinib therapy, cases of clinically apparent liver injury with jaundice are rare. Cases of severe and fatal hepatotoxicity have been reported to the sponsor and monitoring of liver tests during therapy is recommended.

Chemie und Industrie

Pharmakologische Informationen

ATC Code · 3 Einträge

L01XE02

L - Antineoplastic and immunomodulating agents

QL - Antineoplastic and immunomodulating agents

Protein Binding90% primarily to serum albumin and alpha 1-acid glycoproteins (independent of drug concentrations).
Pharmacodynamics · 1 Eintrag

Gefitinib inhibits the intracellular phosphorylation of numerous tyrosine kinases associated with transmembrane cell surface receptors, including the tyrosine kinases associated with the epidermal growth factor receptor (EGFR-TK). EGFR is expressed on the cell surface of many normal cells and cancer cells.

Mechanism of Action · 1 Eintrag

Gefitinib is an inhibitor of the epidermal growth factor receptor (EGFR) tyrosine kinase that binds to the adenosine triphosphate (ATP)-binding site of the enzyme. EGFR is often shown to be overexpressed in certain human carcinoma cells, such as lung and breast cancer cells. Overexpression leads to enhanced activation of the anti-apoptotic Ras signal transduction cascades, subsequently resulting in increased survival of cancer cells and uncontrolled cell proliferation. Gefitinib is the first selective inhibitor of the EGFR tyrosine kinase which is also referred to as Her1 or ErbB-1. By inhibiting EGFR tyrosine kinase, the downstream signaling cascades are also inhibited, resulting in inhibited malignant cell proliferation.

Biological Half-Life48 hours [IV administration]
Metabolism/Metabolites · 2 Einträge

Primarily hepatic via CYP3A4. Three sites of biotransformation have been identified: metabolism of the N-propoxymorpholino-group, demethylation of the methoxy-substituent on the quinazoline, and oxidative defluorination of the halogenated phenyl group.

Gefitinib has known human metabolites that include 4-Defluoro-4-hydroxy Gefitinib and O-Desmethyl Gefitinib.

FDA Pharmacological Classification · 6 Einträge

Zugehörige Reaktionen

7
Reaktionsaufzeichnung erstellen
Reaktionsgleichung von HRID 86437
HRID 86437als Produkt
Reaktionsgleichung von HRID 106154
HRID 106154als Produkt
Reaktionsgleichung von HRID 1432154
HRID 1432154als Edukt
Reaktionsgleichung von HRID 1803014
HRID 1803014als Edukt
Reaktionsgleichung von HRID 1803015
HRID 1803015als Produkt
Reaktionsgleichung von HRID 1803016
HRID 1803016als Produkt
Reaktionsgleichung von HRID 2418923
HRID 2418923als Edukt

Notizen zur Verbindung

Auf dieser SeiteGrundinformationenÜberblickNamen und BezeichnerEigenschaftenSicherheit und RegulatorischesChemie und IndustrieZugehörige ReaktionenNotizen zur Verbindung

Datenbank-Bezeichner

CAS
184475-35-2
PubChem CID
123631
DTXSID
DTXSID8041034
ChEMBL
CHEMBL939
ChEBI
CHEBI:49668
UNII
S65743JHBS
EC Number
643-034-7
Nikkaji
J1.437.124I
Siedepunkt
586.8 · 586.8±50.0 °C(Predicted)
Dichte
1.322 · 1.322±0.06 g/cm3(Predicted)
storage temp.
room temp
Löslichkeit
Soluble in DMSO (up to 40 mg/ml) or in Ethanol (up to 4 mg/ml).
pka
7 · 7.00±0.10(Predicted)
Aggregatzustand
powder
Farbe
white to beige
Stabilität
2 years · Stable for 2 years from date of purchase as supplied. Solutions in DMSO or ethanol may be stored at -20°C for up to 1 month.
InChI
InChI=1S/C22H24ClFN4O3/c1-29-20-13-19-16(12-21(20)31-8-2-5-28-6-9-30-10-7-28)22(26-14-25-19)27-15-3-4-18(24)17(23)11-15/h3-4,11-14H,2,5-10H2,1H3,(H,25,26,27)
InChIKey
XGALLCVXEZPNRQ-UHFFFAOYSA-N
SMILES
N1=C2C(C=C(OCCCN3CCOCC3)C(OC)=C2)=C(NC2=CC=C(F)C(Cl)=C2)N=C1
CAS Datenbank
184475 · 184475-35-2(CAS DataBase Reference)
Drug Induced Liver Injury · 6 Einträge

Drug Induced Liver Injury Rank (DILIrank 2.0)

Gefitinib

vMost-DILI-concern

4

Warnings & precautions

DOI:10.1016/j.drudis.2016.02.015

Effects During Pregnancy and Lactation◉ Summary of Use during Lactation

Sicherheitsdaten

wgk
WGK 3
hs_code
29349990
safety_code
24/25
Speicherklasse
6.1C - Combustible acute toxic Cat.3toxic compounds or compounds which causing chronic effects
Hazard Classifications
Acute Tox. 4 OralAquatic Chronic 1Carc. 2Eye Dam. 1Repr. 1BSkin Irrit. 2STOT RE 2 Oral

S65743JHBS

GEFITINIB

Established Pharmacologic Class [EPC] - Kinase Inhibitor

Mechanisms of Action [MoA] - Protein Kinase Inhibitors

Gefitinib is a Kinase Inhibitor. The mechanism of action of gefitinib is as a Protein Kinase Inhibitor.

GEFITINIB

MeSH Pharmacological Classification · 2 Einträge

Substances that inhibit or prevent the proliferation of NEOPLASMS.

Protein kinase inhibitors that inhibit TYROSINE PROTEIN KINASES.

Absorption, Distribution and Excretion · 4 Einträge

Absorbed slowly after oral administration with a mean bioavailability of 60%. Peak plasma levels occurs 3-7 hours post-administration. Food does not affect the bioavailability of gefitinib.

Elimination is by metabolism (primarily CYP3A4) and excretion in feces. Excretion is predominantly via the feces (86%), with renal elimination of drug and metabolites accounting for less than 4% of the administered dose.

1400 L [IV administration]

595 mL/min [IV administration]

Cellular LocationsExtracellular
Metabolite PathwaysGefitinib Action Pathway
Anwendungen · 1 Eintrag

BeschreibungGefitinib was introduced in Japan as a daily oral monotherapy for the treatment of inoperable or recurrent non-small cell lung cancers (NSCLC). This inhibits autophosphorylation of EGRF and blocks the cascade of intracellular events which have been implicated in the proliferation, survival and metastasis of cancer cells.

Vor- und nachgelagerte Produkte

Vorgelagerte Rohstoffe

Gefitinib Impurity 14